Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responsesFelix Bayerl, Jan P. Böttcher, Sebastian Lacher et al.|Immunity|2023Cited by 176
MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeuticallyEnkhtsetseg Munkhbaatar, Philipp J. Jost, Michelle Dietzen et al.|Nature Communications|2020Cited by 62